EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer
DOI: https://doi.org/10.2147/ijn.s450534
IF: 7.033
2024-04-21
International Journal of Nanomedicine
Abstract:Ernest Moles, 1– 4 David W Chang, 1– 3 Friederike M Mansfeld, 1– 3 Alastair Duly, 1, 2 Kathleen Kimpton, 1 Amy Logan, 1– 4 Christopher B Howard, 5 Kristofer J Thurecht, 5, 6 Maria Kavallaris 1– 4 1 Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, 2052, Australia; 2 UNSW Australian Centre for Nanomedicine, Faculty of Engineering, UNSW, Sydney, NSW, 2052, Australia; 3 School of Clinical Medicine, Faculty of Medicine & Health, UNSW, Sydney, NSW, 2052, Australia; 4 UNSW RNA Institute, Faculty of Science, UNSW, Sydney, NSW, 2052, Australia; 5 Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, QLD, 4072, Australia; 6 Centre for Advanced Imaging, ARC Training Centre for Innovation in Biomedical Imaging Technologies, University of Queensland, St Lucia, QLD, 4072, Australia Correspondence: Ernest Moles; Maria Kavallaris, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, 2052, Australia, Email ; Introduction: Despite improvements in chemotherapy and molecularly targeted therapies, the life expectancy of patients with advanced non-small cell lung cancer (NSCLC) remains less than 1 year. There is thus a major global need to advance new treatment strategies that are more effective for NSCLC. Drug delivery using liposomal particles has shown success at improving the biodistribution and bioavailability of chemotherapy. Nevertheless, liposomal drugs lack selectivity for the cancer cells and have a limited ability to penetrate the tumor site, which severely limits their therapeutic potential. Epidermal growth factor receptor (EGFR) is overexpressed in NSCLC tumors in about 80% of patients, thus representing a promising NSCLC-specific target for redirecting liposome-embedded chemotherapy to the tumor site. Methods: Herein, we investigated the targeting of PEGylated liposomal doxorubicin (Caelyx), a powerful off-the-shelf antitumoral liposomal drug, to EGFR as a therapeutic strategy to improve the specific delivery and intratumoral accumulation of chemotherapy in NSCLC. EGFR-targeting of Caelyx was enabled through its complexing with a polyethylene glycol (PEG)/EGFR bispecific antibody fragment. Tumor targeting and therapeutic potency of our treatment approach were investigated in vitro using a panel of NSCLC cell lines and 3D tumoroid models, and in vivo in a cell line-derived tumor xenograft model. Results: Combining Caelyx with our bispecific antibody generated uniform EGFR-targeted particles with improved binding and cytotoxic efficacy toward NSCLC cells. Effects were exclusive to cancer cells expressing EGFR, and increments in efficacy positively correlated with EGFR density on the cancer cell surface. The approach demonstrated increased penetration within 3D spheroids and was effective at targeting and suppressing the growth of NSCLC tumors in vivo while reducing drug delivery to the heart. Conclusion: EGFR targeting represents a successful approach to enhance the selectivity and therapeutic potency of liposomal chemotherapy toward NSCLC. Keywords: targeted drug delivery, bispecific antibodies, PEGylated liposomal doxorubicin, EGFR targeting, non-small cell lung cancer Graphical Lung cancer is the leading cause of death from cancer worldwide. NSCLC is the most common form accounting for >80% of all cases. Over half of NSCLC patients have developed metastases at the time of diagnosis (stage IV cancer) and 5-year survival remains <26%. Systemic combination chemotherapy is the first-line treatment for NSCLC. 1 However, this has shown limited effectiveness with most intense regimens having reached the limit of tolerability. Newer anticancer agents including tyrosine kinase inhibitors have led to high response rates and prolonged progression-free survival of advanced NSCLC patients in early phase clinical trials. 2,3 Clinical studies in larger cohorts of patents are nevertheless needed to better delineate their potency and safety. There is thus an urgent need to develop new treatment strategies that are less toxic and more effective to improve outcomes for these patients. Systemic drug delivery using liposomal particles is an effective approach to optimize the biodistribution and pharmacokinetic profile of chemotherapy drugs for improved and less-toxic treatment of solid tumors. 4,5 Liposomal particles display an optimal size of 100 to 150 nm for limited renal filtration and greater extravasation and infiltration into the tumor microenvironment. 4 Coating of liposomal particles with methoxy poly -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology